HHS Leaders Peg Sickle Cell Pay Model As Test Case For CGT Access

By Maaisha Osman / June 5, 2025 at 6:11 PM

Top health officials are calling for sweeping changes to the way cell and gene therapies (CGTs) are evaluated, paid for and scaled -- warning that without new approaches, life-saving advances may remain out of reach for most Americans.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

HHS Leaders Peg Sickle Cell Pay Model As Test Case For CGT Access

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.